The guidance raise was modest (low-end only) and Q4 profitability is expected to be softer per management. The Food Ingredients divestiture timeline (close by end of Q2 2027) is the key catalyst for balance sheet delevering and a potential re-rating. Monitor Q4 earnings for Health Biosciences margin trajectory and any updates on the sale process.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 4 $87.67entry
- T+1 · 12d ago −1.49%α +2.91% · $86.36
- T+5 · 6d ago −5.73%α −4.81% · $82.65
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
IFF reported Q3 2026 continuing operations results with net sales of $1.94B (+4% YoY) and adjusted EPS ex-amortization of $0.83, in line with the $0.82 consensus. The company raised the low end of its full-year 2026 guidance: sales now $7.5B-$7.6B (vs $7.4B-$7.6B) and adjusted operating EBITDA $1.55B-$1.60B (vs $1.53B-$1.60B). It also completed a $500M share repurchase and reiterated that the Food Ingredients divestiture is on track to close by end of Q2 2027.
Key Financial Metrics
Key Facts
- Q3 2026 continuing ops net sales $1.94B, +4% reported, +5% currency-neutral comparable vs prior year
- Adjusted EPS ex-amortization $0.83 vs consensus $0.82 (in-line)
- GAAP diluted EPS from continuing ops $(0.50) due to $236M loss on assets held for sale and $34M regulatory costs
- Adjusted operating EBITDA $403M, +5% reported, +6% currency-neutral comparable YoY
- Full-year 2026 guidance raised: sales $7.5B-$7.6B (prev $7.4B-$7.6B), adj EBITDA $1.55B-$1.60B (prev $1.53B-$1.60B)
- Completed $500M accelerated share repurchase program
- Food Ingredients divestiture on track to close by end of Q2 2027
- Net debt to credit adjusted EBITDA at 2.75x as of Sep 30, 2026
- Operating cash flow (combined ops) $820M YTD, +$288M YoY; free cash flow $371M, +$245M YoY
Financial Impact
Q3 continuing ops revenue $1.94B (+4% YoY), adj EPS ex-amort $0.83 in-line with $0.82 consensus; full-year guidance raised modestly
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Taste | $687.0M | +4.0% |
| Health Biosciences | $566.0M | +1.0% |
| Scent | $689.0M | +6.0% |
Risk Factors
- Q4 profitability expected to be softer, particularly in Health Biosciences, due to higher costs and reinvestments
- Ongoing regulatory investigations of fragrance businesses incurred $34M in costs in Q3
- Total debt to trailing net income at 34.5x; net debt to credit adjusted EBITDA at 2.75x
- Food Ingredients divestiture execution risk and potential for lower-than-expected proceeds
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000051253-26-000039 |
| Document: iff-20261103.htm | 0000051253-26-000039 |
| Document: 0000051253-26-000039-index-headers.html | 0000051253-26-000039 |
| Document: 0000051253-26-000039-index.html | 0000051253-26-000039 |
| Document: 0000051253-26-000039.txt | 0000051253-26-000039 |
| 8-K Data (Synthetic) | 0000051253-26-000039 |
Track record
13 reports on IFF
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +17.37% at T+60 after the Jun 1, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $81.16 Now $79.99 −1.44% settles Feb 11
- Nov 3, 202613d ago 8-K Neutral 3/10 Entry $87.67 Now $79.99 −8.76% settles Feb 2
- Nov 3, 202613d ago 8-K Neutral 5/10 Viewing Entry $87.67 Now $79.99 −8.76% settles Feb 2
- Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $93.02 Now $79.99 −14.01% settles Jan 28
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $90.66 Now $79.99 −11.77% settles Jan 26
- Sep 11, 20269w ago ANALYST-UPGRADE Neutral 2/10 Entry $83.61 Now $79.99 −4.33% settles Dec 7
- Aug 10, 202614w ago Insider Cluster Neutral 2/10 Entry $85.00 to $87.67 Now $79.99 −5.89% ▲ +3.14% +3.63% vs SPY
- Jul 20, 202617w ago Press Release Neutral 3/10 Entry $76.26 to $88.20 Now $79.99 +4.89% ▲ +15.66% +11.68% vs SPY
- Jun 23, 202620w ago 8-K Neutral 4/10 Entry $75.83 to $84.91 Now $79.99 +5.49% ▲ +11.97% +9.14% vs SPY
- Jun 9, 202622w ago ANALYST-UPGRADE Bullish 3/10 Entry $75.78 to $86.94 Now $79.99 +5.56% ▲ +14.73% +10.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers